New Stock IPO | Desai Biotech Passes Listing Hearing

SighingCashier · 2026-03-15T13:46:00+00:00

Daycom Biotech Holdings Limited has passed the Hong Kong Exchanges and Clearing (HKEX) listing hearing and plans to list on the Hong Kong Main Board, sponsored by Huatai International. The company focuses on the development of medical imaging products, with offerings including six software applications such as AI AutoVision and multiple commercial medical devices. The core product AI AutoVision is used for chromosomal karyotyping diagnosis, with service scope covering birth defect prevention and assisted reproductive diagnosis.

SighingCashier

2026-03-15 13:46:00

Abstract generation in progress

DeShi Biotechnology Co., Ltd. has passed the Hong Kong Stock Exchange listing hearing and plans to list on the Main Board of Hong Kong, with Huatai International as the sole sponsor.

According to the post-hearing information, the company is a medical device company focused on developing medical imaging products and services. It has developed a diversified product portfolio that can effectively improve diagnostic efficiency and service quality, including six medical imaging software products: the core product AI AutoVision in the registration stage, a commercialized product AutoVision, and four preclinical candidate products; three commercial medical devices; and four main reagents and consumables.

The core product, AI AutoVision, is a chromosomal karyotype-assisted diagnostic software designed for intelligent analysis of chromosomal karyotypes. The company plans to sell this software in China and globally through customized computers with pre-installed software. AI AutoVision is expected to be indicated for prenatal diagnosis of birth defects using amniotic fluid samples and chromosomal karyotype analysis for assisted reproductive diagnosis using peripheral blood samples. It is intended to be approved for use in birth defect prevention, pre-marital and pre-pregnancy screening, and assisted reproduction.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.